Document Type : Original Article


1 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Clinical Biochemistry, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran


Objective: Trace elements deficiency is common among end‑stage renal 
disease (ESRD) patients due to excessive loss during dialysis and the lower intake 
secondary to loss of appetite. Selenium (Se) is a trace element that plays an important 
role in the radical scavenging system and helps the body defend against oxidative 
stress. This study aims to evaluate the effects of Se supplementation on lipid 
profile, anemia, and inflammation indices in ESRD patients. Methods: Fifty-nine 
hemodialysis patients enrolled and were randomly divided into two groups. Two 
hundred microgram Se capsules once daily for the case group and matching placebo 
for the control group were administered for three months. Demographic data 
were collected at the study beginning. Uric acid (UA), anemia and inflammation 
indices, and lipid profiles were recorded at the beginning and the end of the study. 
Findings: UA and UA‑to‑HDL (high‑density lipoprotein) ratio decreased significantly 
in the case group (P < 0.001). The changes in lipid profile were not significant among 
both groups. Hemoglobin slightly increased in the case group, however, it decreased 
significantly in the control group (P = 0.031). High-sensitivity C-reactive protein (hsCRP) decreased in the case group and increased in the control group, however, none 
of these changes were significant. Conclusion: According to the results of this study, 
selenium supplementation in ESRD patients could reduce some risk factors related to 
their mortality, such as the ratio of uric acid to HDL. However, the changes related to 
lipid profile, hemoglobin level and hs-CRP biomarker were not significant.


1. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. 
Global trends in diabetes complications: A review of current 
evidence. Diabetologia 2019;62:3-16.
2. Fujii H, Kono K, Nishi S. Characteristics of coronary artery 
disease in chronic kidney disease. Clinical and experimental 
nephrology 2019;23:725-32.
3. Ishigami J, Matsushita K. Clinical epidemiology of infectious 
disease among patients with chronic kidney disease. Clin Exp 
Nephrol 2019;23:437-47.
4. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, 
Kasiske BL, et al. Controlling the epidemic of cardiovascular 
disease in chronic renal disease: What do we know? What do 
we need to learn? Where do we go from here? National kidney 
foundation task force on cardiovascular disease. Am J Kidney 
Dis 1998;32:853-906.
5. Bossola M, Di Stasio E, Viola A, Leo A, Carlomagno G, 
Monteburini T, et al. Dietary intake of trace elements, minerals, 
and vitamins of patients on chronic hemodialysis. Int Urol 
Nephrol 2014;46:809-15.
6. Brown KM, Arthur JR. Selenium, selenoproteins and human 
health: A review. Public Health Nutr 2001;4:593-9.
7. Reich HJ, Hondal RJ. Why nature chose selenium. ACS Chem 
Biol 2016;11:821-41.
8. Omrani H, Golmohamadi S, Pasdar Y, Jasemi K, Almasi 
A. Effect of selenium supplementation on lipid profile in 
hemodialysis patients. J Renal Inj Prev. 2016;5:179-82. 
9. Khan MS, Dilawar S, Ali I, Rauf N. The possible role of 
selenium concentration in hepatitis B and C patients. Saudi J 
Gastroenterol 2012;18:106-10.
10. Tóth RJ, Csapó J. The role of selenium in nutrition – A review. 
Acta Univ Sapientiae Aliment 2018;11:128-44.
11. Salehi M, Sohrabi Z, Ekramzadeh M, Fallahzadeh MK, 
Ayatollahi M, Geramizadeh B, et al. Selenium supplementation 
improves the nutritional status of hemodialysis patients: 
A randomized, double-blind, placebo-controlled trial. Nephrol 
Dial Transplant 2013;28:716-23.
12. Zachara BA, Gromadzinska J, Palus J, Zbrog Z, Swiech R, 
Twardowska E, et al. The effect of selenium supplementation 
in the prevention of DNA damage in white blood cells of 
hemodialyzed patients: A pilot study. Biol Trace Elem Res 
13. Atapour A, Vahdat S, Hosseini M, Mohamadian H. Effect of 
selenium on triglyceride and total cholesterol, weight gain, and 
physical activity on hemodialysis patients: A randomized doubleblinded controlled trial. Int J Prev Med 2022;13:63.
14. Park JH, Jo YI, Lee JH. Renal effects of uric acid: Hyperuricemia 
and hypouricemia. Korean J Intern Med 2020;35:1291-304.
15. Rysz J, Gluba‑Brzózka A, Rysz‑Górzyńska M, Franczyk B. 
The role and function of HDL in patients with chronic kidney 
disease and the risk of cardiovascular disease. Int J Mol Sci 
16. Liu R, Peng Y, Wu H, Diao X, Ye H, Huang X, et al. Uric 
acid to high-density lipoprotein cholesterol ratio predicts 
cardiovascular mortality in patients on peritoneal dialysis. Nutr 
Metab Cardiovasc Dis 2021;31:561-9.
17. Behera AK, Rathor PK, Nahak SR, Marndi C. The Correlation 
Between High-Density Lipoprotein Cholesterol and Glomerular 
Filtration Rate Estimation in a Community-Based Population. 
European Journal of Molecular & Clinical Medicine 
18. Moore C Jr., Ormseth M, Fuchs H. Causes and significance of 
markedly elevated serum ferritin levels in an academic medical 
center. J Clin Rheumatol 2013;19:324-8.
19. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc 
Nephrol 2012;23:1631-4.
20. Stenvinkel P, Lindholm B. C-reactive protein in end-stage 
renal disease: Are there reasons to measure it? Blood Purif 
21. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The 
kynurenines are associated with oxidative stress, inflammation 
and the prevalence of cardiovascular disease in patients with 
end-stage renal disease. Atherosclerosis 2009;204:309-14.
22. Li W, Xiong L, Fan L, Wang Y, Peng X, Rong R, et al.
Association of baseline, longitudinal serum high-sensitive 
C-reactive protein and its change with mortality in peritoneal 
dialysis patients. BMC Nephrol 2017;18:211.